Because Qsymia (phentermine and topiramate) is protected by patents and exclusivity rights, companies are not allowed to make generic versions of the medication. However, after the first patent expires in June 2020, this could change, unless lawsuits or new patents are filed.
Qsymia® (phentermine and topiramate) is a prescription weight loss medication. It is approved for use in people who are obese or people who are overweight with at least one weight-related medical condition, such as high blood pressure or diabetes.
Qsymia is made by Catalent Pharma Solutions, LLC, for Vivus, Inc. It is currently protected by patents and exclusivity rights that prevent any generic Qsymia from being manufactured in the United States.
This first patent for Qsymia is set to expire in June 2020. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to extend or delay this exclusivity period. This could include such things as lawsuits or other patents for new Qsymia uses. Once the patents and exclusivity rights expire, there may be several companies that manufacture a generic Qsymia drug.
No -- phentermine and topiramate are the active ingredients in Qsymia (and also in other medications, separately), not generic versions of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version of a medicine, the original medicine must have gone off-patent, and another company besides the original manufacturer must make the product.